Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.
Many researchers suspect that low genetic barrier to resistance allowed HIV to adapt to this seemingly powerful three-drug combination.
James
John S
JS
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D000068698:Tenofovir; D017211:Treatment Failure; D000099227:Abacavir
D000225:Adenine; D015224:Dideoxynucleosides; D019259:Lamivudine; D063065:Organophosphonates; D000068698:Tenofovir; D000099227:Abacavir